ArticleBreast cancer (Dove Medical Press)2018

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.

Anna Forsythe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.